MyPerioPath(SM) detects the presence and quantityof specific bacteria associated with periodontal disease. MyPerioID(SM)PST(R), licensed through a marketing, sales and Train tickets distribution agreementwith Interleukin Genetics, provides a means of assessing an individual'sgenetic risk for periodontal disease.The company is also developing an oral HPV test for use in assessing risksassociated with oral cancer. Thereafter, OralDNA intends to develop abroader menu of clinical laboratory tests for use in oral medicine.Contact:Robert P WalkerSr. LONDON, Jan 15 (Reuters) - Austria's Erste Bank (ERST.VI)plans to issue a three-year euro-denominated benchmark bond, thefirst issue under a 6 billion euro ($7.9 billion) tickets for Jason Aldean governmentguarantee programme, IFR reported on Thursday.
07/11 - 08/11 Procure Jason Aldean Tickets performing in Missouri State Fairground, Riverbend Music Center. Jason Aldean is performing in Sedalia, Cincinnati and Mountain View. Jason Aldean tickets
07/11 - 08/11 Obtain Train Tickets playing in Tanglewood Music Center, Thunder Valley Casino. Train is playing in Lenox, Lincoln and Erie. Train tickets
07/11 - 09/11 Capture San Francisco Giants Tickets playing in Dodger Stadium, Great American Ball Park. San Francisco Giants is playing in Los Angeles, Cincinnati and Houston. San Francisco Giants tickets
Barclays Capital, BNP Paribas, JP Morgan and Erste Bankitself will manage the triple-A rated deal, said IFR Markets, aThomson Reuters online news and market analysis service (Reporting by Jonathan Cable). TEL AVIV, Israel, tickets for Train January 15 /PRNewswire-FirstCall/ Ronex Holdings,Limited Partnership ("Ronex"), an Israeli limited partnership wholly-owned bythe FIMI private equity funds, announced today that it has commenced a cashtender offer to purchase up to 2,038,977 ordinary shares of Retalix Ltd.(Nasdaq: RTLX) for $6.00 per share. If more than the maximum number of sharesoffered to be purchased in the tender offer are tendered, Ronex will purchaseshares on a pro rata basis.Ronex, a controlling shareholder of Retalix, currently owns 3,253,367ordinary shares of Retalix, representing approximately 16.0 Train ticket of Retalix'soutstanding shares and, together with Retalix's founders, Messrs. BarryShaked and Brian Cooper with whom Ronex had entered into a shareholders'agreement, Ronex may be deemed to beneficially have shared power to vote over5,038,331 shares, representing approximately 24.7 Train of Retalix's outstandingshares.
If the full number of shares is purchased in the tender offer, Ronexwill own approximately 26.0 of Retalix's outstanding shares and, by virtueof the shareholders' agreement may be deemed to hold 34.7 of Retalix'soutstanding shares (together with the shares beneficially owned by Messrs.Shaked and Cooper).On January 12, 2009, the last trading day before Ronex Jason Aldean tickets announced toRetalix its intention to launch the offer, the closing sale price of theRetalix shares was $5.88 on Nasdaq and NIS 23.66 ($6.07 based on an exchangerate of NIS 3.8950 per United States dollar as of January San Francisco Giants ticket 12, 2009) on theTel Aviv San Francisco Giants Stock Exchange.The initial period of the tender offer and withdrawal rights is scheduledto expire at 10:00 Jason Aldean ticket a.m., New York time, or 5:00 p.m., Israel time, onFebruary 19, 2009, unless the initial period is extended by Ronex. Asrequired by Israeli law, if the conditions to the offer are satisfied as ofthe completion of the initial offer period, Ronex will provide an additionalperiod of four calendar days during which shareholders may tender theirshares. The tender offer is not conditioned on the receipt of financing or theapproval of the board of directors of Retalix.The complete terms and conditions of the tender offer, includingimportant U.S. and Israeli income and withholding tax considerations relatingto the tender offer, are contained in the Offer to Purchase included as anexhibit to the Tender Offer Statement on Schedule TO filed today with theU.S. Securities and Exchange Commission (SEC) and with the Israeli SecuritiesAuthority (ISA). Allshareholders of Retalix should read the tender offer materials which arebeing filed today by Ronex.
Shareholders of Retalix should read the tenderoffer materials because they contain important information about the tenderoffer. The tender offer materials and other filed documents will be availableat no charge on the SEC's website at http:// and on the ISA'swebsite at http://, and will also be made availablewithout charge to all shareholders by contacting Georgeson, Inc., theinformation agent for the tender offer, at (212) 440-9800 or toll free (800)456-6497. Shareholders are urged to read these materials carefully beforemaking any decision with respect to the tender offer.Forward-Looking Statements: This press release may containforward-looking statements. The accuracy of such statements is subject to anumber of risks, uncertainties and assumptions that may cause actual resultsto differ materially from those projected, including, but not limited to, theeffect of general economic conditions, political events and fluctuations inthe share price of Retalix. Ronex undertakes no obligation to publicly updateany forward-looking statements, whether as a result of new information,future events or otherwise.About Ronex Holdings, Limited tickets for San Francisco Giants Partnership: Ronex Holdings, LimitedPartnership, is an Israeli limited partnership formed in 2008 for the solepurpose of acquiring shares Jason Aldean in Retalix. Its limited partners are FIMI IsraelOpportunity Fund II, Limited Partnership, FIMI Opportunity II Fund, L.P.,FIMI Israel Opportunity IV, Limited Partnership and FIMI Opportunity IV, L.P.which are limited partnerships that are part of a group of private equityfunds known as the FIMI Funds. The FIMI Funds invest in companies that arepredominantly located in Israel or that have significant San Francisco Giants tickets ties or relations toIsrael.Ronex Holdings Contact:Address: Rubinstein House, 37 Menachem Begin Rd., Tel-Aviv 67137, IsraelTel: 972-3-565-2244E-mail: OURCERonex Holdings, Limited PartnershipRonex Holdings Contact: Address: Rubinstein House, 37 Menachem Begin Rd.,Tel-Aviv 67137, Israel, Tel: 972-3-565-2244, E-mail: .